New Enterprise Associates

Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer care through innovative diagnostic and therapeutic solutions. The company's CELsignia diagnostic platform analyzes living tumor cells from patients to identify the specific abnormal cellular processes driving their cancer, enabling personalized treatment options. Celcuity is developing the CELsignia HSF test to diagnose new sub-types of HER2-negative breast cancer, as well as the CELsignia MP test to identify multiple cancer sub-types across various types, including breast, lung, colon, ovarian, kidney, and bladder cancers. In addition to its diagnostic efforts, Celcuity is advancing a lead therapeutic candidate, gedatolisib, a potent pan-PI3K and mTOR inhibitor, which is currently being evaluated in a Phase 3 clinical trial for patients with HR+/HER2- advanced breast cancer. Founded in 2011, Celcuity aims to transform the treatment landscape for patients with cancer by providing targeted therapies tailored to their unique disease profiles.

Developer of an online teleconsultation platform designed to guide women during and after menopause. The company's platform has online access to specialized doctors, science-backed pieces of information and treatments with conversations and information about effective care for changing hormones, enabling women to live longer and healthier lives.

InCarey is a comprehensive medical service platform based in Shanghai, China, founded in 2011. The company specializes in the management of patients with chronic and vertical diseases, integrating medical, pharmaceutical, and insurance resources to deliver a one-stop solution for long-term healthcare needs. Its cloud-based platform offers professional disease management services, facilitating one-on-one interactions between doctors and patients. Additionally, InCarey's e-commerce capabilities enable users to obtain medications for major diseases efficiently. The platform is designed to address the complexities of chronic disease management, providing innovative payment solutions and a streamlined approach to healthcare services.

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.

Vori Health is an all-inclusive medical and health provider practicing a holistic, integrated approach starting with musculoskeletal care. It offers full-service physical medicine and rehabilitation care, physical therapy, prescriptions, imaging and lab ordering, health coaching, nutritional guidance, community support, and premium instructional content. The team consists of carefully selected, board-certified physicians and licensed healthcare providers, and provides health services that are accessible at the click of a button from the comfort, convenience, and privacy of a patient's home. The company was founded in 2020 and is headquartered in San Francisco, California.

Spiras Health is a healthcare company focused on enhancing patient outcomes by providing home-based care for individuals with complex chronic illnesses. The company extends specialist care into patients' homes through a multidisciplinary team of clinicians. By utilizing telehealth services, two-way digital communications, and remote patient monitoring, Spiras Health aims to improve patients' quality of life while simultaneously reducing costs associated with avoidable hospitalizations. This approach not only increases access to necessary medical services but also addresses the challenges faced by patients managing chronic conditions.

AllyAlign Health, Inc. is a care management company dedicated to supporting patients with chronic and complex medical conditions. Founded in 2013 and based in Glen Allen, Virginia, the company utilizes an active care management platform that facilitates real-time, collaborative care across various boundaries. This platform connects patients with care teams, providers, and home and community-based services, ensuring access to vital health information, care plans, and benefits needed for informed decision-making. Users can easily view, share, create, and update information according to their roles, with mobile and web-based options available for convenient access. The company maintains a central, HIPAA-compliant database that integrates information from diverse sources, such as electronic health records, lab tests, and pharmacy data, while employing semantic data modeling to present meaningful clinical insights.

Vori Health is an all-inclusive medical and health provider practicing a holistic, integrated approach starting with musculoskeletal care. It offers full-service physical medicine and rehabilitation care, physical therapy, prescriptions, imaging and lab ordering, health coaching, nutritional guidance, community support, and premium instructional content. The team consists of carefully selected, board-certified physicians and licensed healthcare providers, and provides health services that are accessible at the click of a button from the comfort, convenience, and privacy of a patient's home. The company was founded in 2020 and is headquartered in San Francisco, California.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Strive Health, LLC, founded in 2018 and headquartered in Denver, Colorado, focuses on providing comprehensive solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enabled clinical model that enhances patient outcomes and experiences throughout the healthcare journey. Strive Health collaborates with innovative payors and providers to transform kidney care by utilizing predictive analytics and comparative data to identify at-risk patients. Additionally, the company emphasizes early intervention through redesigned primary care practices to treat kidney disease before it necessitates dialysis. By offering education, training, and care management, Strive Health aims to reduce inpatient utilization and promote the adoption of home dialysis, ultimately improving the overall quality of care for patients with chronic kidney disease.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

Cardionomic, Inc. develops a catheter-based medical device aimed at treating acute decompensated heart failure (ADHF) through neuromodulation. This innovative technology electrically stimulates cardiac nerves to enhance the heart's pumping action, which is crucial for improving cardiac output, renal blood flow, urine production, and pharmacological tolerance. The device is inserted into the right pulmonary artery via the internal jugular vein and selectively stimulates autonomic nerves that control ventricular contractility without altering heart rate. By targeting the root cause of ADHF, Cardionomic's therapy not only increases contractility but also leads to reductions in plasma norepinephrine and B-type natriuretic peptide, both of which are biomarkers of chronic heart failure. Established in 2007 and headquartered in New Brighton, Minnesota, Cardionomic aims to enhance patient outcomes in acute heart failure management.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.

THE WELL is a modern membership-based wellness club designed for busy urban professionals. They bring together Western doctors and Eastern healers to collaborate, developing online content and personalized products and experiences that empower their community to take greater agency for their health. The company recognizes both the benefits of Western medicine and the wisdom of Eastern healing and have built a science-backed ecosystem for wellness. The Well's integrative medicine doctors, health coaches, and skilled practitioners work together under one roof to build customized plans uniquely suited to each member and their goals.

Strive Health, LLC, founded in 2018 and headquartered in Denver, Colorado, focuses on providing comprehensive solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enabled clinical model that enhances patient outcomes and experiences throughout the healthcare journey. Strive Health collaborates with innovative payors and providers to transform kidney care by utilizing predictive analytics and comparative data to identify at-risk patients. Additionally, the company emphasizes early intervention through redesigned primary care practices to treat kidney disease before it necessitates dialysis. By offering education, training, and care management, Strive Health aims to reduce inpatient utilization and promote the adoption of home dialysis, ultimately improving the overall quality of care for patients with chronic kidney disease.

Lungpacer Medical Inc. is a medical device company based in Vancouver, Canada, with an additional office in Exton, Pennsylvania. Founded in 2009, the company specializes in developing therapeutic solutions for critically ill patients who require mechanical ventilation. Its primary product, the Lungpacer DPT System, is a diaphragm pacing system designed to preserve and restore the strength of the diaphragm muscle. This innovative system utilizes the body's nervous system to stimulate the diaphragm, enabling repetitive exercises that help rebuild muscle strength and endurance. By addressing diaphragm muscle disuse atrophy, Lungpacer aims to improve the overall respiratory health of patients, facilitating better outcomes in critical care settings.

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.

MORE Health, Inc. is a healthcare technology company that offers a cloud-based platform designed to enhance physician collaboration. This platform connects patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. Key features include a clinical database containing medical histories, hospital records, and lab results, as well as medical imaging tools and HIPAA-compliant video conferencing for discussions. The company also provides a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and secure medical record services for traveling employees. Originally established as a concierge service for individuals, MORE Health now extends its offerings to U.S. companies as an employer-sponsored health benefit, facilitating access to top physicians for serious medical issues through Co-Diagnosis or Independent Second Opinion services. Founded in 2013 and based in Foster City, California, MORE Health collaborates with renowned medical institutions, including The George Washington Medical Faculty Associates, Boston Children's Hospital, and UCLA Health, with the aim of becoming a virtual global hospital for serious illnesses.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.

CareZone is a healthcare platform focused on simplifying personal health management and pharmacy delivery services. It offers tools that automate prescription refill reminders, track medical appointments, and provide controlled access to health information for family members and caregivers. This integrated approach allows users to organize their health data and coordinate care effectively from a single interface, making it easier for individuals and families to manage their healthcare needs.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

MORE Health, Inc. is a healthcare technology company that offers a cloud-based platform designed to enhance physician collaboration. This platform connects patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. Key features include a clinical database containing medical histories, hospital records, and lab results, as well as medical imaging tools and HIPAA-compliant video conferencing for discussions. The company also provides a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and secure medical record services for traveling employees. Originally established as a concierge service for individuals, MORE Health now extends its offerings to U.S. companies as an employer-sponsored health benefit, facilitating access to top physicians for serious medical issues through Co-Diagnosis or Independent Second Opinion services. Founded in 2013 and based in Foster City, California, MORE Health collaborates with renowned medical institutions, including The George Washington Medical Faculty Associates, Boston Children's Hospital, and UCLA Health, with the aim of becoming a virtual global hospital for serious illnesses.

Radiology Partners Holdings, LLC, founded in 2012 and headquartered in Manhattan Beach, California, operates within the healthcare sector as a radiology practice center. The company is dedicated to transforming the way radiologists deliver services, catering to hospitals, referring physicians, and patients. By focusing on enhancing the efficiency and effectiveness of radiology services, Radiology Partners aims to improve patient care and support healthcare facilities in meeting their diagnostic needs.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

Metavention, Inc., established in 2012 and headquartered in Dover, Delaware, specializes in the development of trans-catheter devices aimed at modulating sympathetic nervous system activity. These innovative devices address the issues of over-active sympathetic nerves that contribute to elevated glucose levels and abnormal liver function. By employing standard interventional vascular techniques, Metavention provides healthcare professionals with a novel tool for diagnosing and treating patients with Type 2 diabetes. The company focuses on enhancing treatment options for this condition, ultimately improving patient outcomes.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Curisium Inc. operates as a healthcare technology and services company that develops blockchain based platform. It facilitates patient-centric contracting for payers, providers, and life science companies. Curisium Inc. was formerly known as Holosense Inc. The company was founded in 2016 and is headquartered in Manhattan Beach, California. As of July 20, 2020, Curisium Inc. operates as a subsidiary of HealthVerity, Inc.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

SafeRide, Inc. is a digital health platform that specializes in non-emergency medical transportation (NEMT) services, enabling healthcare providers to efficiently book and manage rides for patients. Founded in 2015 and headquartered in San Francisco, the company offers a mobile application that allows users to schedule transportation quickly, receive appointment reminders, and track rides in real-time for enhanced safety and quality. SafeRide's services not only help prevent no-shows but also assist in identifying and managing at-risk patients before their conditions worsen. With a network that spans major cities including Los Angeles, Seattle, Portland, St. Louis, and New York, SafeRide aims to improve access to life-sustaining care for vulnerable populations while enhancing the overall patient experience and reducing healthcare costs.

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.

OrphoMed, Inc. develops therapies for irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Its pipeline includes ORP-101, a chemical entity designed to create a stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology; ORP-105, a non-addictive, centrally-acting, non-opiate analgesic; and ORP-110, a metabolically-stable, non-depletory cystic fibrosis transmembrane regulator potentiator. OrphoMed, Inc. was incorporated in 2015 and is based in San Francisco, California.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Radiology Partners Holdings, LLC, founded in 2012 and headquartered in Manhattan Beach, California, operates within the healthcare sector as a radiology practice center. The company is dedicated to transforming the way radiologists deliver services, catering to hospitals, referring physicians, and patients. By focusing on enhancing the efficiency and effectiveness of radiology services, Radiology Partners aims to improve patient care and support healthcare facilities in meeting their diagnostic needs.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that focuses on developing monoclonal antibody-based therapies for cancer treatment. The company's lead product, sacituzumab govitecan, is an antibody-drug conjugate targeting metastatic triple-negative breast cancer, where it is positioned as a third-line treatment in the United States. Additionally, Immunomedics is advancing several other candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company also explores collaborative clinical efforts with major pharmaceutical partners to enhance the development and application of its products. Founded in 1982, Immunomedics aims to deliver innovative treatments to patients with serious diseases, leveraging its capabilities to drive scientific advancements and operational effectiveness. As of late 2020, it operates as a subsidiary of Gilead Sciences, Inc.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

Rotation Medical Inc. specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant consists of a collagen scaffold designed to be affixed to damaged rotator cuff tendons, providing effective management and protection for tendon injuries. This system offers a surgical solution for patients with small rotator cuff tears and serves as an additional protective layer for larger tears. Founded in 2006 and headquartered in Plymouth, Minnesota, Rotation Medical was previously known as Denali Medical Inc. and rebranded in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.

Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

LinkDoc Technology Limited develops medical data solutions and oncology big data platforms. It offers clinical structured data for oncology hospitals and hospitals to assist hospitals in solving scientific and clinical problems. The company was founded in 2014 and is headquartered in Beijing, China.

NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Cardionomic, Inc. develops a catheter-based medical device aimed at treating acute decompensated heart failure (ADHF) through neuromodulation. This innovative technology electrically stimulates cardiac nerves to enhance the heart's pumping action, which is crucial for improving cardiac output, renal blood flow, urine production, and pharmacological tolerance. The device is inserted into the right pulmonary artery via the internal jugular vein and selectively stimulates autonomic nerves that control ventricular contractility without altering heart rate. By targeting the root cause of ADHF, Cardionomic's therapy not only increases contractility but also leads to reductions in plasma norepinephrine and B-type natriuretic peptide, both of which are biomarkers of chronic heart failure. Established in 2007 and headquartered in New Brighton, Minnesota, Cardionomic aims to enhance patient outcomes in acute heart failure management.

CrowdMed, Inc. is a healthcare technology company based in San Francisco, California, established in 2012. It utilizes a prediction market platform to address complex medical issues by tapping into the collective intelligence of a network of medical detectives, which includes licensed physicians, medical students, and other healthcare professionals. This innovative approach allows CrowdMed to provide patients with potential diagnoses and solutions for undiagnosed or chronic symptoms that have eluded traditional medical practices. By combining the insights of numerous contributors, CrowdMed aims to deliver accurate and timely medical suggestions, thereby streamlining the healthcare process. The company seeks to become a trusted resource for millions of patients facing challenging medical conditions.

Pager, Inc. is a digital health technology company that operates an on-demand service platform, connecting patients with healthcare services in various settings, including their homes and workplaces. The company offers a mobile application that addresses urgent care needs, such as infections, allergies, and other health concerns. Pager provides a comprehensive suite of services, including teleconsultations, nurse chat, vaccination, prescription delivery, and aftercare support. Its platform is designed for payers, providers, and employers, facilitating quick and convenient access to care while promoting effective navigation through the healthcare system. Pager's technology enables seamless communication via chat, voice, and video, and integrates artificial intelligence and data tools to enhance collaboration among healthcare teams. Serving approximately 10 million covered lives across the United States and parts of Latin America, Pager aims to deliver a personalized healthcare experience that simplifies patient interactions with care providers. The company was founded in 2013 and is headquartered in New York.

Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.

ClarVista Medical, Inc. is a California-based company that specializes in developing innovative products for ophthalmic conditions. Founded in 2012 as a spin-off from a medical device incubator, the company focuses on its flagship product, the HARMONI modular intraocular lens system. This system is designed to optimize vision during cataract surgery by allowing for the initial positioning of the lens and the easy exchange of the lens optic, thus enabling healthcare practitioners to tailor procedures to meet individual patient needs. ClarVista Medical has established a robust portfolio of intellectual property and has conducted clinical studies to validate its technology. The company has secured significant funding to advance the development of the HARMONI system and to pursue necessary regulatory approvals.

Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

MORE Health, Inc. is a healthcare technology company that offers a cloud-based platform designed to enhance physician collaboration. This platform connects patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. Key features include a clinical database containing medical histories, hospital records, and lab results, as well as medical imaging tools and HIPAA-compliant video conferencing for discussions. The company also provides a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and secure medical record services for traveling employees. Originally established as a concierge service for individuals, MORE Health now extends its offerings to U.S. companies as an employer-sponsored health benefit, facilitating access to top physicians for serious medical issues through Co-Diagnosis or Independent Second Opinion services. Founded in 2013 and based in Foster City, California, MORE Health collaborates with renowned medical institutions, including The George Washington Medical Faculty Associates, Boston Children's Hospital, and UCLA Health, with the aim of becoming a virtual global hospital for serious illnesses.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

GSMS is a pharmaceutical company that specializes in labeling and serialization services, as well as repackaging and distribution. The company caters primarily to the Federal government, supplying generic therapeutic treatments to various entities, including mail-order pharmacies, federal and state pharmacies, and local government programs. GSMS focuses on meeting the unique labeling and dispensing requirements of its clients while ensuring that its products are offered at an affordable price. Through its comprehensive services, the company aims to enhance the accessibility of essential therapeutic treatments across multiple sectors.

LinkDoc Technology Limited develops medical data solutions and oncology big data platforms. It offers clinical structured data for oncology hospitals and hospitals to assist hospitals in solving scientific and clinical problems. The company was founded in 2014 and is headquartered in Beijing, China.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Rotation Medical Inc. specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant consists of a collagen scaffold designed to be affixed to damaged rotator cuff tendons, providing effective management and protection for tendon injuries. This system offers a surgical solution for patients with small rotator cuff tears and serves as an additional protective layer for larger tears. Founded in 2006 and headquartered in Plymouth, Minnesota, Rotation Medical was previously known as Denali Medical Inc. and rebranded in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.